Medicamen Biotech standalone net profit declines 33.57% in the March 2022 quarter

Sales rise 11.85% to Rs 22.75 crore

Net profit of Medicamen Biotech declined 33.57% to Rs 2.75 crore in the quarter ended March 2022 as against Rs 4.14 crore during the previous quarter ended March 2021. Sales rose 11.85% to Rs 22.75 crore in the quarter ended March 2022 as against Rs 20.34 crore during the previous quarter ended March 2021.

For the full year,net profit rose 19.38% to Rs 14.91 crore in the year ended March 2022 as against Rs 12.49 crore during the previous year ended March 2021. Sales rose 4.81% to Rs 115.45 crore in the year ended March 2022 as against Rs 110.15 crore during the previous year ended March 2021.

ParticularsQuarter EndedYear EndedMar. 2022Mar. 2021% Var.Mar. 2022Mar. 2021% Var.Sales22.7520.34 12 115.45110.15 5 OPM %21.8023.94 -20.4117.78 - PBDT4.745.05 -6 23.8819.28 24 PBT3.224.64 -31 18.1116.76 8 NP2.754.14 -34 14.9112.49 19

Powered by Capital Market - Live News